WAYNE, Pa., Sept. 18, 2015
/PRNewswire/ -- Ryan & Maniskas, LLP announces that a
class action lawsuit has been filed in the United States District
Court for the District of Maryland
on behalf of persons who purchased or acquired the shares of
Northwest Biotherapeutics, Inc. ("Northwest Biotherapeutics" or the
"Company") (NASDAQ: NWBO) between March 8,
2013 and August 20, 2015,
inclusive (the "Class Period").
Northwest Biotherapeutics shareholders may, no later than
October 26, 2015, move the Court for
appointment as a lead plaintiff of the Class. If you
purchased shares of Northwest Biotherapeutics and would like to
learn more about these claims or if you wish to discuss these
matters and have any questions concerning this announcement or your
rights, contact Richard A. Maniskas,
Esquire toll-free at (877) 316-3218 or to sign up online,
visit:
www.rmclasslaw.com/cases/nwbo.
The Complaint alleges that throughout the Class Period
defendants concealed that: (1) claims regarding positive results
from the DCVax-Direct Trial (the "Results") were based on
preliminary and unconfirmed trial results; (2) the Results had not
been reviewed or analyzed by the hospitals conducting the trials;
(3) the Company's statements about the Results were derived from
patient case report forms sent to the Company only because it
sponsored the study; (4) the Company was the subject of an
aggressive stock promotion campaign including promoters using false
identities and credentials; (5) German regulators required
additional information from the Company in order for the Company's
DCVax-L Trial to continue uninterrupted; and (6) as a result of the
above, the Company's financial statements were materially false and
misleading.
SS&B is also investigating whether allegations in news
reports that Northwest Biotherapeutics has used undisclosed, paid
stock promoters to increase the value of its shares, which SS&B
believes may have been a waste of corporate assets that exposed the
Company to liability.
If you are a member of the class, you may, no later than
October 26, 2015, request that the
Court appoint you as lead plaintiff of the class. A lead
plaintiff is a representative party that acts on behalf of other
class members in directing the litigation. In order to be
appointed lead plaintiff, the Court must determine that the class
member's claim is typical of the claims of other class members, and
that the class member will adequately represent the class.
Under certain circumstances, one or more class members may
together serve as "lead plaintiff." Your ability to share in
any recovery is not, however, affected by the decision whether or
not to serve as a lead plaintiff. You may retain Ryan &
Maniskas, LLP or other counsel of your choice, to serve as your
counsel in this action.
Ryan & Maniskas, LLP is a national shareholder litigation
firm. Ryan & Maniskas, LLP is devoted to protecting the
interests of individual and institutional investors in shareholder
actions in state and federal courts nationwide. To learn more
about the class action process, please visit:
www.rmclasslaw.com.
CONTACT: Ryan & Maniskas, LLP
Richard A. Maniskas, Esquire
995 Old
Eagle School Rd., Suite 311
Wayne, PA 19087
484-588-5516
877-316-3218
www.rmclasslaw.com/cases/nwbo
rmaniskas@rmclasslaw.com
Logo -
http://photos.prnewswire.com/prnh/20121112/MM11729LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/ryan--maniskas-llp-announces-class-action-lawsuit-against-northwest-biotherapeutics-inc-300145776.html
SOURCE Ryan & Maniskas, LLP